Anteris Technologies Global Corp. is involved in designing, developing and commercializing cutting-edge medical devices to restore healthy heart function. The company's lead product includes DurAVR(R). Anteris Technologies Global Corp. is based in BRISBANE, Australia.
| Revenue (Most Recent Fiscal Year) | $2.70M |
| Net Income (Most Recent Fiscal Year) | $-76.29M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.92 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 2.41 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.38 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.74 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.58 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.68 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 36.06M |
| Free Float | 34.62M |
| Market Capitalization | $166.25M |
| Average Volume (Last 20 Days) | 0.25M |
| Beta (Past 60 Months) | -- |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.00% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |